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The number of mechanisms that have evolved in
microbes to subvert the immune response seems
limitless. Tubercle bacilli have found a novel way to
coat themselves with the C3 complement protein and
invade macrophages by interactions with complement
receptors.
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It has become increasingly apparent over recent years that
micro-organisms of many kinds have evolved the capacity to
subvert the host’s immune response; in addition, a variety
of mechanisms of subversion have been described [1–3].
For example, helminths coat themselves with host materials
in order to hide their antigenic identity; other micro-organ-
isms produce specific proteases to destroy antibody mol-
ecules in the bowel; and some bacteria — by mechanisms
that are still not clear — prevent the insertion of the mem-
brane-attack complex of complement into their plasma
membranes. This complex is formed by the terminal com-
ponents of the complement cascade, which provides an
important arm of defence against extracellular pathogens.
Much recent interest has concentrated on the microbial
production of proteins analogous to host protective factors,
including the expression of complement control proteins
and Fc receptors. One of the major surface glycoproteins
of the Herpes simplex virus has complement receptor 1
(CR1) activity [4], in that it binds to the complement pro-
teins C3b and C4b, and vaccinia virus has been demon-
strated to secrete a complement control protein [5].
Herpesvirus saimiri carries in its genome a gene encoding
a protein that closely resembles the CD59 complement
control protein of the squirrel monkey, its natural host [6]:
the biological significance of this protein is not yet known
but is currently under study [7]. Both trypanosomes and
schistosomes are sensitive to complement-mediated lysis
in the developmental stages outside the human host but
rapidly become complement-resistant after invading the
human host. It is now known that this acquisition of resis-
tance is accompanied by the expression of specific pro-
teins that have activities similar to those of the human
complement control proteins CD59 and decay accelerat-
ing factor [8]. Candida albicans expresses a molecule
resembling the integrin complement receptor CR3 which
allows the organism to adhere to endothelium [9]. The
expression of this CR3-like molecule is induced by the
presence of glucose in the medium and is essential for the
organism to grow systemically, therefore providing a clear
example whereby a subverting molecule acts as an
‘aggressin’ — a factor promoting the virulence of a micro-
organism.
A novel and extremely subtle mechanism of invasion by
mycobacteria has recently been described by Schorey et al.
[10]. Pathogenic mycobacteria are intracellular parasites of
macrophages and have acquired the capacity to enter
macrophages through several classes of receptor expressed
on the surface of macrophages: receptors for the C3 com-
plement component (CR1, CR3 and CR4); mannose
receptors; and class A scavenger receptors [11]. In order
for complement-receptor-mediated entry to occur,
however, the mycobacteria need to be coated with C3
fragments. Although this coating is normally achieved by
activation of the alternative complement pathway,
Schorey et al. [10] have identified another mechanism: the
mycobacteria produce on their outer surface a protein that
is functionally analogous to C4b in that it combines with a
fragment of the complement protein C2. (The authors call
this fragment C2a on historical grounds but, to conform
with the conventions that govern the naming of comple-
ment fragments, it should be termed C2b — the larger
cleavage product of C2 that contains its serine protease
site. To be consistent with the Schorey paper, the name
C2a is used in this dispatch for this larger C2 fragment.)
The complex of the mycobacterial C4b-like protein and
C2a forms a C3-converting enzyme (C3 convertase) on the
membrane of the organism and allows the deposition of
C3b onto its membrane. Bound C3b then promotes com-
plement activation and amplifies the effects of the classi-
cal complement pathway, leading ultimately to invasion of
the host macrophage by the mycobacterium.
It remains to be determined how closely the interaction of
the mycobacterial protein with C2a resembles that of C4b
and C2a (Figure 1). The authors point out that C4b does
not normally bind C2a from the fluid phase, although it
does bind native C2. However, the early work on this
topic [12,13] was carried out before C4b was known to be
rapidly broken down by the complement regulatory pro-
teins, Factor I and C4-binding protein (C4bp) [14]. It may
be the case that the mycobacterial C4b-like protein is
resistant to such breakdown in a similar way to cobra
venom factor, which behaves like a Factor I-resistant C3b
protein. The paper does not reveal whether, like the inter-
action between C4b and C2, the interaction of the
mycobacterial C4b-like protein with C2a requires magne-
sium. Also, the studies by Schorey et al. [10] do not show
whether, in the presence of C3b, the enzyme formed on
the surface of the mycobacteria can cleave C5 to initiate
the formation of the membrane-attack complex — an
interesting point as there is an allotype of human C4
(C4A6) which forms a C3 convertase with C2a but does
not allow the cleavage of C5 [15].
The C4b-like microbial protein has not yet been isolated
and we therefore have no information about its structure.
It is not known whether this protein is attached to the
membrane via an amide or an ester linkage, in a similar
way to the fixation mechanism of C4, and whether this
protein has any sequence homology to C4 or C3. The
reaction between C4b and C2a is also species-specific, like
many of the ‘lock and key’ interactions of complement
components, and it would be interesting to find out
whether this reaction, which is reported to occur with
horse serum as well as human serum, also occurs with
other mammalian species.
Does this mechanism of putting C3 fragments onto the
mycobacterial surface have any advantage over the tradi-
tional method of alternative pathway activation? One pos-
sible benefit could be that the C3b fixed by this
mechanism is less resistant to cleavage into its inactivated
form, iC3b, by the complement control proteins Factor I
and Factor H than C3b fixed by the alternative pathway in
which the ‘protected surface’ hinders the action of Factor
I. (C3b bound to the ‘protected surface’ is able to bind
Factor B but is protected from binding Factor H.) This
decreased resistance to cleavage could be important if the
major receptors used for mycobacterial entry into
macrophages are CR3 and CR4, because these leukocyte
integrin receptors react only with iC3b and not with C3b
itself. This explanation, however, is at variance with the
data presented by the authors showing that CR1 is the
major complement receptor used by Mycobacterium avium
[10]. Another possible explanation is that the C2b capture
mechanism may work at sites where there is insufficient
plasma to support alternative pathway activation, which
requires a high concentration of complement components.
A final point of interest with regard to these findings is that
they provide a possible mechanism of selection that
explains the relatively frequent occurrence of C2 defi-
ciency in Caucasian populations. This deficiency is the
most common complement deficiency in Caucasoids, but it
is exceptionally rare in Black and Oriental populations [16].
The MHC haplotype that carries C2 deficiency has been
conserved, suggesting that the deficiency can be attributed
to a particular mutation that has been selected in the rela-
tively recent past. It has often been proposed that the
selective pressure in maintaining such mutations is to
increase resistance to infectious diseases, and tuberculosis
has been suggested as a selective agent for other muta-
tions, such as those giving rise to α1 antitrypsin deficiency
[17] and to cystic fibrosis [18], which are common only in
Caucasoids. Here, for the first time, we have a possible
mechanism by which C2 deficiency might protect against
tuberculosis and it is the first mechanism that has been
proposed for any selective advantage for C2 deficiency.
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Figure 1
Schematic drawing of the part of the classical
complement pathway that is relevant to the
mycobacterial invasion mechanism described
by Schorey et al. [10]. See text for details.
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